NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer

scientific article published on 01 September 1990

NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer is …
instance of (P31):
scholarly articleQ13442814
review articleQ7318358

External links are
P698PubMed publication ID2202842

P433issue11
P407language of work or nameEnglishQ1860
P304page(s)1444-1450
P577publication date1990-09-01
P1433published inThe Journal of the American Medical AssociationQ1470970
P1476titleNIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer
P478volume264

Reverse relations

cites work (P2860)
Q831726733-T MRI with phased-array surface coil in the local staging of rectal cancer
Q35993810A Primer on the Current State-of-the-Science Neoadjuvant and Adjuvant Therapy for Patients with Locally Advanced Rectal Adenocarcinomas
Q36125075A panel discussion of controversies and challenges in the adjuvant treatment of colon cancer.
Q37355442A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer
Q36667516A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer
Q36616783A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer.
Q34147006A team approach to improving colorectal cancer services using administrative health data
Q81381752Access to care and satisfaction in colorectal cancer patients
Q35133471Adequacy of the National Quality Forum's Colon Cancer Adjuvant Chemotherapy Quality Metric: Is 4 Months Soon Enough?
Q34488296Adherence to clinical practice guidelines for adjuvant chemotherapy for colorectal cancer in a Canadian province: a population-based analysis
Q33860245Adjuvant Chemotherapy for Patients with Stage III Colon Cancer: Results from a CDC-NPCR patterns of care study
Q37076532Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology.
Q37026757Adjuvant and neoadjuvant chemoradiation or radiotherapy in rectal cancer--a review focusing on open questions
Q34627277Adjuvant and neoadjuvant radiotherapy and concurrent radiochemotherapy for rectal cancer
Q36101826Adjuvant and neoadjuvant treatment of resectable, locally advanced, rectal carcinoma with radiation therapy and chemotherapy
Q34255956Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-α
Q26775099Adjuvant chemotherapy for rectal cancer: Is it needed?
Q34631210Adjuvant chemotherapy for stage II colon cancer with poor prognostic features
Q30780611Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data
Q33374271Adjuvant chemotherapy in elderly patients (>or=75 yr) completely resected for colon cancer stage III compared to younger patients: toxicity and prognosis
Q39601118Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer
Q46896343Adjuvant chemotherapy with folinic acid and 5-fluorouracil in patients with locally advanced rectal cancer previously treated by preoperative radiochemotherapy and curative tumor resection
Q84396469Adjuvant radiotherapy following total mesorectal excision for stage IIA rectal cancer: is it beneficial?
Q36239072Adjuvant systemic chemotherapy for stages II and III colon cancer after complete resection: a clinical practice guideline
Q36130803Adjuvant therapy for adenocarcinoma of the rectum
Q81679190Adjuvant therapy for colon cancer
Q83161252Adjuvant therapy for colon cancer
Q42868640Adjuvant therapy for colon cancer: learning from the past to inform the future
Q37462241Adjuvant therapy for rectal cancer
Q35767246Adjuvant therapy for rectal cancer in the elderly
Q91831015Adjuvant therapy for stages II and III colon cancer: risk stratification, treatment duration, and future directions
Q37072502Adjuvant treatment of rectal cancer: improving patient selection
Q36025983Advances and challenges in treatment of locally advanced rectal cancer
Q55427621Advances in the management of rectal cancer.
Q45386283Age and factors associated with access and time to post-operative adjuvant chemotherapy in colon cancer: a French epidemiological study
Q47851170Ageism in rectal carcinoma? Treatment and outcome variations
Q71626706Alteration in lymphocyte phenotype associated with administration of adjuvant levamisole and 5-fluorouracil
Q31106341An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer.
Q27024427An update on microRNAs as colorectal cancer biomarkers: where are we and what's next?
Q33607161Anatomic basis of sharp pelvic dissection for curative resection of rectal cancer
Q33866565Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (1989-2002)
Q73451649Angiogenesis and dendritic cell density are not correlated with metachronous distant metastasis in curatively operated rectal cancer
Q80713667Are we undertreating rectal cancer in the elderly? An epidemiologic study
Q45256282Assessing the initiation and completion of adjuvant chemotherapy in a large nationwide and population-based cohort of elderly patients with stage-III colon cancer
Q36534769Association between the availability of medical oncologists and initiation of chemotherapy for patients with stage III colon cancer
Q47627901Better Late than Never? Adherence to Adjuvant Therapy Guidelines for Stage III Colon Cancer in an Underserved Region
Q55353989CDX2 expression is concordant between primary colorectal cancer lesions and corresponding liver metastases independent of chemotherapy: a single-center retrospective study in Japan.
Q36611654CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a phase II.
Q31138958Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Data base
Q30822062Cancer registries can provide evidence-based data to improve quality of care and prevent cancer deaths.
Q58914739Cancer surgery in the elderly
Q64117622Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance)
Q36394634Characteristics affecting survival after locally advanced colorectal cancer in Quebec
Q73236924Chemotherapy of Colorectal Cancer
Q35978879Chemotherapy use in stage III colon cancer: a National Cancer Database analysis
Q42027206Chronic myelogenous leukemia after postoperative adjuvant S-1 therapy for rectal cancer: a case report
Q33794082Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer: a population-based study
Q47121565Clinical-Pathological Correlation of KRAS Mutation Status in Metastatic Colorectal Adenocarcinoma
Q36871965Colon cancer stem cells: controversies and perspectives
Q37172593Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study
Q33947455Colorectal cancer treatment
Q34844579Colorectal cancer: from epidemiology to current treatment
Q33408350Combining information from cancer registry and medical records data to improve analyses of adjuvant cancer therapies
Q30422446Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer
Q45716452Comparison of adjuvant FOLFOX4 chemotherapy and oral UFUR/LV following adjuvant FOLFOX4 chemotherapy in patients with stage III colon cancer subsequent to radical resection
Q30422095Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.
Q35071455Completion of therapy by Medicare patients with stage III colon cancer
Q35585939Conclusions from a study of venous invasion in stage IV colorectal adenocarcinoma
Q37145772Concordance with clinical practice guidelines for adjuvant chemotherapy in patients with stage I-III colon cancer: experience in 2 Canadian provinces
Q35445092Consensus statement: the 16th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; September 5-6, 2014
Q47737573Controversial issues in radiotherapy for rectal cancer: a systematic review
Q47235105Cost and effectiveness of follow-up examinations in patients with colorectal cancer resected for cure in a French population-based study
Q44492666Cost effectiveness of adding folinic acid to fluorouracil plus levamisole as adjuvant chemotherapy in patients with colon cancer in Germany
Q26824553Current treatment of rectal cancer adapted to the individual patient
Q50422213Cytotoxic T lymphocyte response to peptide vaccination predicts survival in stage III colorectal cancer.
Q70504417DNA aneuploidy is an independent factor of poor prognosis in pancreatic and peripancreatic cancer
Q41823848Detection of Biomarkers with Solid-Phase Proximity Ligation Assay in Patients with Colorectal Cancer
Q35769649Detection of venous invasion in surgical specimens of colorectal carcinoma: the efficacy of various types of tissue blocks
Q84049962Diabetes mellitus negatively impacts survival of patients with colon cancer, particularly in stage II disease
Q91691310Diabetic ketoacidosis caused by fulminant type 1 diabetes during adjuvant chemotherapy for colon cancer: A case report
Q53584611Diagnostic value of measuring liver volume for detecting occult hepatic metastases from colorectal or gastric cancer.
Q35071410Differences among the elderly in the treatment costs of colorectal cancer: how important is race?
Q80562303Do young colon cancer patients have worse outcomes?
Q73050010Does anastomotic leakage affect functional outcome after rectal resection for cancer?
Q43923184Downregulation of caspase-10 predicting poor survival after resection of stage II colorectal cancer
Q36711475Drug treatment of colorectal cancer. Current status
Q53137607Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome.
Q37133361Effectiveness of adjuvant chemotherapy for elderly patients with lymph node-positive colorectal cancer.
Q38298226Effectiveness of gene expression profiling for response prediction of rectal cancer to preoperative radiotherapy
Q83821349Effects of postoperative adjuvant radiotherapy on recurrence and survival in stage III rectal cancer
Q33746878Efficacy of postoperative concurrent chemoradiation for resectable rectal cancer: a single institute experience
Q34282863Emergency surgery for colorectal cancer does not result in nodal understaging compared with elective surgery
Q30484649Endorectal ultrasound: its role in the diagnosis and treatment of rectal cancer
Q27014984Epigenetics meets radiation biology as a new approach in cancer treatment
Q47950050ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery.
Q52949271Evaluating toxicity in neoadjuvant radio-chemotherapy of rectal cancer
Q35067307Evaluation of relapse-free survival in T3N0 colon cancer: the role of chemotherapy, a multicentric retrospective analysis
Q39390635Evolving role of neoadjuvant therapy in rectal cancer
Q30502576Explaining black-white differences in receipt of recommended colon cancer treatment
Q53061569Extended lymph node dissection in colorectal cancer surgery. Reliability and reproducibility in assessments of operative reports.
Q82904914Extent of mesorectal tumor invasion as a prognostic factor after curative surgery for T3 rectal cancer patients
Q34778099FOLFIRI Is Tolerable after Subtotal Colectomy - A Patient with Familial Adenomatous Polyposis Who Developed Advanced Rectal Cancer
Q36609950Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients.
Q37416816Feasibility of adequate resectable rectal cancer treatment in a third-level hospital
Q37508622Follow-up plans after treatment of primary colon and rectum cancer
Q36104000Getting knit-PI3Ky: PIK3CA mutation status to direct multimodality therapy?
Q38651907Health care disparities among octogenarians and nonagenarians with stage II and III rectal cancer.
Q37701707High expression of miR-181c as a predictive marker of recurrence in stage II colorectal cancer.
Q47128241Hospital academic status and value of care for nonmetastatic colon cancer
Q36416460How do surgeons decide to refer patients for adjuvant cancer treatment? Protocol for a qualitative study
Q34465977Hypomethylation-associated up-regulation of TCF3 expression and recurrence in stage II and III colorectal cancer
Q80955233Hypoxia, angiogenesis and apoptosis markers in locally advanced rectal cancer
Q35693475Impact of "Killer Immunoglobulin-Like Receptor /Ligand" Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival
Q89502186Impact of Adjuvant Therapy Type on Survival in Stage II/III Rectal Cancer Without Preoperative Chemoradiation: A Korean Multicenter Retrospective Study
Q47140514Impact of neoadjuvant and adjuvant radiotherapy on disease-specific survival in patients with stages II-IV rectal cancer
Q42794535Impact of neoadjuvant chemoradiation on pathologic response and survival of patients with locally advanced rectal cancer
Q33791360Impact of the new AJCC staging system and adjuvant treatment in rectal cancer
Q38474003Impact on Prognosis of Lymph Node Micrometastasis and Isolated Tumor Cells in Stage II Colorectal Cancer
Q34932625Impression of prognosis regarding pathologic stage after preoperative chemoradiotherapy in rectal cancer
Q47959037Improved survival in an Asian cohort of young colorectal cancer patients: an analysis of 523 patients from a single institution
Q36352848In search of synergy: strategies for combining interventions at multiple levels
Q34469631In the era of total mesorectal excision: adjuvant radiotherapy may be unnecessary for pT3N0 rectal cancer
Q46616424Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-alpha
Q41735144Increasing utilization and predictors of hematopoietic growth factors in patients diagnosed with colorectal cancer: findings from a large national population-based cohort in the USA, 1992-2009.
Q33646009Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings
Q37463523Initial treatment for newly diagnosed elderly colorectal cancer patients: patterns of care in Italy and the United States.
Q36306673Interval between Surgery and Radiation Therapy Is an Important Prognostic Factor in Treatment of Rectal Cancer.
Q33909869Is acute dyspnea related to oxaliplatin administration?
Q51803069Is adjuvant chemotherapy beneficial to high risk stage II colon cancer? Analysis in a single institute.
Q37533235Is adjuvant radiotherapy warranted in resected pT1-2 node-positive rectal cancer?
Q36300533Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer
Q37946252Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer.
Q36324953Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer.
Q47712300Karyopherin α-2 is a reliable marker for identification of patients with high-risk stage II colorectal cancer
Q38453832LEMMA: a language for easy medical models analysis
Q42601143Laparoscopic surgery for the curative treatment of rectal cancer: results of a Chinese three-center case-control study
Q81688022Late outcomes of colorectal cancer treatment: a FECS-EUROCARE study
Q36972881Levamisole/fluorouracil. A review of their pharmacology and adjuvant therapeutic use in colorectal cancer
Q37088033Local recurrence after rectal cancer treatment in Manitoba
Q34571377Local staging of rectal cancer: the current role of MRI.
Q43436444Long-term efficacy of preoperative radiotherapy for locally advanced low rectal cancer
Q45017990Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer
Q74492663Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy
Q34766318Long-term survival and recurrence outcomes following surgery for distal rectal cancer.
Q85084914Long-term survival results of surgery alone versus surgery plus UFT (Uracil and Tegafur)-based adjuvant therapy in patients with stage II colon cancer
Q33302869Longitudinal, population-based study of racial/ethnic differences in colorectal cancer survival: impact of neighborhood socioeconomic status, treatment and comorbidity
Q35666090Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy
Q35703248Management of rectal cancer
Q36097091Management of stage II/III rectal cancer
Q34751755Mature Results of a Prospective Randomized Trial Comparing 5-Flourouracil with Leucovorin to 5-Flourouracil with Levamisole as Adjuvant Therapy of Stage II and III Colorectal Cancer- The Israel Cooperative Oncology Group (ICOG) Study
Q36500021Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer.
Q90429127MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside
Q33868392Modern management of rectal cancer: a 2006 update
Q36615471Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study
Q90415336Molecular Imaging of Cancer Stem Cells for Assessment of Rectal Cancer
Q36551503Mortality risk after preoperative versus postoperative chemotherapy and radiotherapy in lymph node-positive rectal cancer
Q55013743Multicenter, phase II clinical trial of peptide vaccination with oral chemotherapy following curative resection for stage III colorectal cancer.
Q35920508Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future
Q37408813Neo-adjuvant radiotherapy in rectal cancer
Q39172475Neoadjuvant Treatment for Locally Advanced Rectal Cancer: New Concepts in Clinical Trial Design
Q37292444Neoadjuvant chemoradiation for rectal cancer reduces lymph node harvest in proctectomy specimens
Q28365788Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience
Q26796352Neoadjuvant chemoradiation therapy and pathological complete response in rectal cancer
Q41692918Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer.
Q50000489Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial
Q42121875Neoadjuvant oral vs. infusional chemoradiotherapy on locally advanced rectal cancer: Prognostic factors
Q37158143Neoadjuvant treatment of rectal cancer: where are we now?
Q33849039Neoadjuvant vs adjuvant pelvic radiotherapy for locally advanced rectal cancer: Which is superior?
Q35095353New developments in therapy for colorectal cancer
Q43138615New perspectives in treatment decision for integrated management of rectal cancer: multimodal research for multimodal treatments
Q48571098Non-inferiority multicenter prospective randomized controlled study of rectal cancer T2-T3s (superficial) N0, M0 undergoing neoadjuvant treatment and local excision (TEM) vs total mesorectal excision (TME).
Q35951764Oncologic Outcomes and Risk Factors for Recurrence after Tumor-specific Mesorectal Excision of Rectal Cancer: 782 Cases
Q36403043Oncologic Outcomes of Stage IIIA Colon Cancer for Different Chemotherapeutic Regimens
Q79378349Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival
Q34247372Optimising treatment for resectable rectal cancer: is preoperative therapy beneficial?
Q35779359Overall Survival of Stage III Colon Cancer with Only One Lymph Node Metastasis Is Independently Predicted by Preoperative Carcinoembryonic Antigen Level and Lymph Node Sampling Status.
Q36511751Overexpression of PAK-1 is an independent predictor of disease recurrence in colorectal carcinoma
Q38403572Overexpression of protein S100A4 is independently associated with overall survival in stage C colonic cancer but only in cytoplasm at the advancing tumour front.
Q36365456Pathological correlation with diffusion restriction on diffusion-weighted imaging in patients with pathological complete response after neoadjuvant chemoradiation therapy for locally advanced rectal cancer: preliminary results
Q41068800Pattern of recurrence in rectal carcinoma: implications for the design of (future) studies on adjuvant therapy
Q36824126Patterns of Colorectal Cancer Care in the United States: 1990-2010.
Q37256284Patterns of Pelvic Radiotherapy in Patients with Stage II/III Rectal Cancer
Q34771979Patterns of local recurrence in rectal cancer after a multidisciplinary approach
Q36370711Patterns of recurrence following liver resection for colorectal metastases: effect of primary rectal tumor site
Q47580575Pelvic sidewall involvement in recurrent rectal cancer
Q55455144Perioperative Serum Carcinoembryonic Antigen Ratio Is a Prognostic Indicator in Patients With Stage II Colorectal Cancer.
Q53179192Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma.
Q34344547Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297.
Q33799243Population-based study of effectiveness of neoadjuvant radiotherapy on survival in US rectal cancer patients according to age.
Q44841956Positive peritoneal washing cytology is a potential risk factor for the recurrence of curatively resected colorectal cancer
Q37564794Possible contribution of IMRT in postoperative radiochemotherapy for rectal cancer: analysis on 1798 patients by prediction model.
Q24201072Postoperative adjuvant chemotherapy in rectal cancer operated for cure
Q80111840Postoperative irradiation for rectal cancer increases the risk of small bowel obstruction after surgery
Q35588277Pre-operative and post-operative radiotherapy and rectal cancer
Q39823759Predictive clinicopathologic factors for limited response of T3 rectal cancer to combined modality therapy
Q43969739Predictive value of (18)FDG PET-CT for tumour response in patients with locally advanced rectal cancer treated by preoperative chemoradiotherapy
Q35866157Predictors of Long-Term Quality of Life for Survivors of Stage II/III Rectal Cancer in the Cancer Care Outcomes Research and Surveillance Consortium
Q35537282Predictors of referral for adjuvant therapy for colorectal cancer.
Q86823678Preoperative chemoradiotherapy for clinically diagnosed T3N0 rectal cancer
Q53528706Preoperative evaluation of pelvic lateral lymph node of patients with lower rectal cancer: comparison study of MR imaging and CT in 53 patients.
Q57035666Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma
Q37158196Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial.
Q33406632Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society
Q36616636Preoperative short-term radiation therapy (25 Gy, 2.5 Gy twice daily) for primary resectable rectal cancer (phase II).
Q43406325Preoperative versus postoperative chemoradiotherapy in stage T3, N0 rectal cancer
Q45288286Present treatment strategies for rectal carcinoma
Q37656817Primary colonic signet ring cell carcinoma in a young patient.
Q34928303Profiling hospitals by survival of patients with colorectal cancer
Q37600725Prognostic Value of E-cadherin-, CD44-, and MSH2-associated Nomograms in Patients With Stage II and III Colorectal Cancer
Q37730438Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review
Q34202487Prognostic significance of depth of gross or microscopic perirectal fat invasion in T3 N0 M0 rectal cancers following sharp mesorectal excision and no adjuvant therapy
Q35596125Prognostic significance of the allelic loss of the BRCA1 gene in colorectal cancer
Q77620951Prognostic significance of tumor markers in colorectal cancer patients: DNA index, S-phase fraction, p53 expression, and Ki-67 index
Q50079903Prognostic value of the detection of lymph node micrometastases in colon cancer
Q33589855Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy--long-term results
Q34734413Provider-based research networks may improve early access to innovative colon cancer treatment for African Americans treated in the community
Q34026017Quality-of-life and surgical treatments for rectal cancer--a longitudinal analysis using the California Cancer Registry
Q34360966Quantifying limitations in chemotherapy data in administrative health databases: implications for measuring the quality of colorectal cancer care.
Q37536719Quantitative proteomics reveals that distant recurrence-associated protein R-Ras and Transgelin predict post-surgical survival in patients with Stage III colorectal cancer
Q35916635Race and Insurance Differences in the Receipt of Adjuvant Chemotherapy Among Patients With Stage III Colon Cancer
Q43636065Racial and ethnic disparities in outcomes with radiation therapy for rectal adenocarcinoma
Q36503071Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002?
Q30418988Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults
Q57272317Racial disparities in stage-specific colorectal cancer mortality: 1960-2005
Q92716703Radiation therapy for rectal cancer
Q83419632Radiotherapy in rectal cancer: development, adequacy and radiotherapy utilisation rate. A comparative analysis with the most frequent tumour sites
Q83071483Radiotherapy: Preoperative chemoradiotherapy for rectal cancer
Q34296147Reasons physicians do not recommend and patients refuse adjuvant chemotherapy for stage III colon cancer: a population based chart review
Q30484651Rectal cancer staging
Q47110810Recurrence-associated gene signature optimizes recurrence-free survival prediction of colorectal cancer
Q58913807Reduced Lymph Node Yield in Rectal Carcinoma Specimen After Neoadjuvant Radiochemotherapy Has No Prognostic Relevance
Q35878821Referral to medical oncology: a crucial step in the treatment of older patients with stage III colon cancer
Q36572508Relationship between diversion colitis and quality of life in rectal cancer
Q44755635Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology
Q27021105Review of systemic therapies for locally advanced and metastatic rectal cancer
Q33627785Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes
Q28384895Secular trends in mortality from common cancers in the United States by educational attainment, 1993-2001
Q89502167Selection of Adjuvant Treatment Without Neoadjuvant Chemoradiotherapy for Patients With Rectal Cancer: Room for Further Investigation
Q44226585Selective use of preoperative chemoradiotherapy for T3 rectal cancer can be justified: analysis of local recurrence
Q88881301Selective use of radiation for locally advanced rectal cancer: one size does not fit all
Q31140547Sentinel lymph node mapping in colon cancer
Q33745103Serum cellular apoptosis susceptibility protein is a potential prognostic marker for metastatic colorectal cancer
Q35103614Stage III colon cancer at Baylor University Medical Center at Dallas and the Baylor Sammons Cancer Center: experience from 2000 to 2004
Q26823217Stem cells, colorectal cancer and cancer stem cell markers correlations
Q37072492Stratification of rectal cancer stage for selection of postoperative chemoradiotherapy: current status.
Q37310011Striking similarities in genetic aberrations between a rectal tumor and its lung recurrence
Q33897653Surgery and adjuvant chemotherapy use among veterans with colon cancer: insights from a California study.
Q45038133Surgical therapy of liver metastases. Therapeutic procedures, results and prognostic factors
Q55082844Survival Contradiction Between Stage IIA and Stage IIIA Rectal Cancer: A Retrospective Study.
Q35011194Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population
Q51770013Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting.
Q44447446Synchronous postoperative adjuvant chemoradiation therapy for locally advanced carcinoma of the rectum.
Q28084403Systematic Review: Adjuvant Chemotherapy for Locally Advanced Rectal Cancer with respect to Stage of Disease
Q73164021T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy
Q36216141The C-Reactive Protein to Albumin Ratio as a Predictor of Severe Side Effects of Adjuvant Chemotherapy in Stage III Colorectal Cancer Patients
Q37011670The Colon Health and Life-Long Exercise Change trial: a randomized trial of the National Cancer Institute of Canada Clinical Trials Group
Q49531454The Impact of Novel Radiation Treatment Techniques on Toxicity and Clinical Outcomes In Rectal Cancer
Q30452275The accuracy of multi-detector row computerized tomography in staging rectal cancer compared to endoscopic ultrasound
Q37913985The current landscape of locally advanced rectal cancer
Q33432354The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort study
Q36895084The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients
Q36101379The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer
Q35306161The extramural metastasis might be categorized in lymph node staging for colorectal cancer.
Q34216044The impact of delayed chemotherapy on its completion and survival outcomes in stage II colon cancer patients.
Q44985394The modern abdominoperineal excision: the next challenge after total mesorectal excision
Q38359377The neoadjuvant treatment of rectal cancer: a review
Q50494337The pathological assessment of mesorectal excision: implications for further treatment and quality management.
Q37462225The pathologist's role in rectal cancer patient assessments
Q38965328The positive impact of surgical quality control on adequate lymph node harvest by standardized laparoscopic surgery and national quality assessment program in colorectal cancer
Q37670882The role of 3-D endorectal ultrasound in rectal cancer: our experience
Q48254485The role of adjuvant chemotherapy in stage II colorectal cancer patients
Q37694845The survival and clinicopathological differences between patients with stage IIIA and stage II rectal cancer: An analysis of 12,036 patients in the SEER database
Q34234928Therapeutic approaches in the management of locally advanced rectal cancer
Q92189101Total neoadjuvant therapy in locally advanced rectal cancer: Role of systemic chemotherapy
Q87884153Total number of lymph node metastases is a more significant risk factor for poor prognosis than positive lateral lymph node metastasis
Q43648443Toxicity and effects of adjuvant therapy in colon cancer: results of the German prospective, controlled randomized multicenter trial FOGT-1.
Q30417975Translating research into practice: the role of provider-based research networks in the diffusion of an evidence-based colon cancer treatment innovation
Q36351882Treatment of locally advanced rectal cancer: controversies and questions
Q38170032Treatment of stage II-III rectal cancer patients
Q33552813Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients
Q37699262Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients
Q37340518Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer
Q47141257Use of Adjuvant Chemotherapy among Stage II Colon Cancer Patients in 10 Population-Based National Program of Cancer Registries
Q46884830Use of surgical procedures and adjuvant therapy in rectal cancer treatment: a population-based study
Q58130112Utilization of short-course radiation therapy for patients with nonmetastatic rectal adenocarcinoma in the United States
Q36343876Value of diffusion-weighted imaging in the detection of viable tumour after neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer: comparison with T2 weighted and PET/CT imaging
Q37524471Wound dehiscence after abdominoperineal resection for low rectal cancer is associated with decreased survival
Q77537083[Adjuvant and neoadjuvant therapy of rectal carcinoma. The current status]
Q77335763[An addendum to the article by C. Rödel, W. Hohenberger, R. Sauer. Adjuvant and neoadjuvant radiochemotherapy of rectal carcinoma. Strahlenther Onkol 1998; 174: 497-504 (Nr. 10)]
Q72519240[Developments up to now and current status of adjuvant chemo- and radiotherapy in colonic and rectal carcinoma]
Q80700849[Problems in the treatment of upper rectal carcinoma]
Q50936160[The acute toxicity of the simultaneous radiochemotherapy of rectal carcinoma].

Search more.